Pulmonary embolism (PE) is a common disorder that is accompanied by significant
morbidity and mortality. Although anticoagulation is the standard treatment for PE …

Currently, guidelines and recommendations are important tools to help physicians related
with acute pulmonary embolism patient care to weigh the benefits and risks of …

Current guidelines recommend anticoagulation (AC) for low and intermediate-risk
pulmonary embolism (PE) and systemic thrombolysis (tPA) for high risk (massive) PE. How …

Aim: To report all-cause and PE related short term mortality by clinical severity of PE and to
identify any missed opportunities for thrombolysis. Background: Mortality related to …

Venous thrombo-embolism (VTE) is the third most common cause of death among
thrombosis-related conditions (behind ischaemic heart disease and ischaemic stroke), 1 and …

Recommendations for appropriate administration of thrombolysis in PE have sparked
debate and controversy for the past 30 years. Sometimes, those preparing journal symposia …

only 0.1% to 3.8% of patients with PE, 16, 18 and mechanisms to identify this subset of
patients a priori are not available. It is unfortunate that clinical outcomes were not reported in …

Thrombolytic therapy leads to a more rapid rate of resolution of pulmonary embolic
obstruction then standard therapy with heparin. This has been documented by angiography …

Contemporary classification of acute pulmonary embolism (PE) severity is based on the risk
of early death, which is influenced by demographic factors, comorbidity, and the functional …

Introduction and objectives Acute pulmonary embolism (PE) is the third most frequent acute
cardiovascular syndrome. Systemic thrombolysis is the treatment of choice in patients with …